Published in J Clin Oncol on October 01, 2003
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res (2010) 1.74
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst (2006) 1.74
p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med (2010) 1.00
Hunk is required for HER2/neu-induced mammary tumorigenesis. J Clin Invest (2011) 0.91
Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer. Carcinogenesis (2009) 0.84
Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. J Med Food (2013) 0.80
Regulation of hormonal therapy resistance by cell cycle machinery. Gene Ther Mol Biol (2008) 0.79
Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma. Anticancer Res (2011) 0.76
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (2011) 5.63
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2008) 4.50
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst (2002) 3.54
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 3.24
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res (2002) 2.57
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys (2007) 2.54
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol (2009) 2.50
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res (2004) 2.36
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst (2007) 2.34
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res (2009) 2.30
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol (2012) 2.09
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res (2004) 1.97
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol (2007) 1.90
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol (2009) 1.90
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer (2003) 1.88
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 1.72
Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg (2008) 1.67
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol (2006) 1.63
High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica (2012) 1.62
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res (2008) 1.57
Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat (2007) 1.54
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer (2003) 1.50
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer (2010) 1.50
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg (2002) 1.48
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol (2004) 1.47
Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res (2012) 1.46
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res (2008) 1.46
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr (2004) 1.45
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol (2006) 1.44
Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat (2008) 1.42
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol (2007) 1.42
Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology (2012) 1.42
Short-term rhythmic proliferation of human breast cancer cell lines: surface effects and fractal growth patterns. J Pathol (2002) 1.41
Long-term results of dose density therapy in patients with aggressive lymphoma. Ann Hematol (2004) 1.40
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene (2002) 1.35
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat (2007) 1.35
Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom (2005) 1.35
Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst (2005) 1.34
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2012) 1.32
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31